Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway

Fig. 6

SHH002-hu1 weakens the ability of residual TNBC cells to initiate tumors and the self-renew capacity of TNBC cells enhanced by Bevacizumab. a. Representative images of isolated MDA-MB-231/MDA-MB-468 tumors replanted in secondary nude mice. b. Mice were implanted with tumor cells from control/Bevacizumab-treated/Bevacizumab + SHH002-hu1-treated mice. Each secondary nude mouse was inoculated with 1 × 104 cells in one of the inguinal mammary fat pads. The growth of tumors was monitored weekly. Data were given as the mean ± SD (n = 5), *p < 0.05, **p < 0.01. c. 5 × 103 cells isolated from MDA-MB-231/MDA-MB-468 xenografts were cultured in low attachment 6 well culture plates for 2 weeks to form the mammospheres, bar = 100 μm. d. Quantitation of the mammosphere-forming efficiency. The numbers of mammospheres (> 60 μm) were recorded after 2 weeks of culture. Data were presented as the mean ± SD, n = 3, *p < 0.05, **p < 0.01

Back to article page
\